Ethical issues in two parallel trials of personalised criteria for implantation of implantable cardioverter defibrillators for primary prevention: the PROFID project—a position paper
Nikolaos Dagres,
Gerhard Hindricks,
Dick Willems,
Marieke Bak,
Hanno Tan,
Georg Lindinger,
Ayca Kocar,
Alireza Seperhi Shamloo,
Georg Schmidt
Affiliations
Nikolaos Dagres
Leipzig Heart Institute GmbH, Leipzig, Sachsen, Germany
Gerhard Hindricks
Heart Center Leipzig at University of Leipzig and Leipzig Heart Institute, Leipzig, Germany
Dick Willems
Ethics, Law, and Humanities, Amsterdam Public Health, Amsterdam UMC Locatie Meibergdreef, Amsterdam, The Netherlands
Marieke Bak
Ethics, Law, and Humanities, Amsterdam Public Health, Amsterdam UMC Locatie Meibergdreef, Amsterdam, The Netherlands
Hanno Tan
Department of Experimental Cardiology, Amsterdam UMC Locatie AMC, Amsterdam, The Netherlands
Georg Lindinger
Institute for Health Care Management and Health Sciences, University of Bayreuth, Bayreuth, Bayern, Germany
Ayca Kocar
Institute for Health Care Management and Health Sciences, University of Bayreuth, Bayreuth, Bayern, Germany
Alireza Seperhi Shamloo
Leipzig Heart Institute GmbH, Leipzig, Sachsen, Germany
Georg Schmidt
Medizinische Klinik und Poliklinik, Technische Universität München, München, Bayern, Germany
Aim To discuss ethical issues related to a complex study (PROFID) involving the development of a new, partly artificial intelligence-based, prediction model to enable personalised decision-making about the implantation of an implantable cardioverter defibrillator (ICD) in postmyocardial infarction patients, and a parallel non-inferiority and superiority trial to test decision-making informed by that model.Method The position expressed in this paper is based on an analysis of the PROFID trials using concepts from high-profile publications in the ethical literature.Results We identify ethical issues related to the testing of the model in the treatment setting, and to both the superiority and the non-inferiority trial. We underline the need for ethical-empirical studies about these issues, also among patients, as a parallel to the actual trials. The number of ethics committees involved is an organisational, but also an ethical challenge.Conclusion The PROFID trials, and probably other studies of similar scale and complexity, raise questions that deserve dedicated parallel ethics and social science research, but do not constitute a generic obstacle. A harmonisation procedure, comparable to the Voluntary Harmonization Procedure (VHP) for medication trials, could be needed for this type of trials.